|
Valoración de DCF de Fate Therapeutics, Inc. (destino)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Fate Therapeutics, Inc. (FATE) Bundle
¡Simplifique la valoración de Fate Therapeutics, Inc. (Fate) con esta calculadora DCF personalizable! Con Real Fate Therapeutics, Inc. (destino) financieras y entradas de pronóstico ajustables, puede probar escenarios y descubrir el valor razonable de Fate Therapeutics, Inc. (Fate) en minutos.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.7 | 31.4 | 55.8 | 96.3 | 63.5 | 97.9 | 150.7 | 232.1 | 357.5 | 550.6 |
| Revenue Growth, % | 0 | 194.33 | 77.66 | 72.44 | -34.03 | 54.02 | 54.02 | 54.02 | 54.02 | 54.02 |
| EBITDA | -94.2 | -125.0 | -211.1 | -294.6 | -172.2 | -97.9 | -150.7 | -232.1 | -357.5 | -550.6 |
| EBITDA, % | -882.06 | -397.65 | -378.08 | -305.95 | -271.09 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 2.2 | 3.1 | 5.9 | 13.8 | 18.3 | 16.4 | 25.3 | 38.9 | 60.0 | 92.4 |
| Depreciation, % | 20.53 | 9.82 | 10.48 | 14.29 | 28.78 | 16.78 | 16.78 | 16.78 | 16.78 | 16.78 |
| EBIT | -96.4 | -128.1 | -217.0 | -308.4 | -190.5 | -97.9 | -150.7 | -232.1 | -357.5 | -550.6 |
| EBIT, % | -902.59 | -407.47 | -388.56 | -320.23 | -299.86 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 221.4 | 482.9 | 615.9 | 436.2 | 315.2 | 97.9 | 150.7 | 232.1 | 357.5 | 550.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | 5.5 | 8.7 | 38.5 | 1.8 | 14.9 | 22.9 | 35.2 | 54.3 | 83.6 |
| Account Receivables, % | 0 | 17.54 | 15.54 | 39.96 | 2.87 | 15.18 | 15.18 | 15.18 | 15.18 | 15.18 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 0.000003181269 | 0 | 0.000001038422 | 0 | 0.000000844 | 0.000000844 | 0.000000844 | 0.000000844 | 0.000000844 |
| Accounts Payable | 5.8 | 6.3 | 8.6 | 8.3 | 4.7 | 20.7 | 31.9 | 49.2 | 75.7 | 116.7 |
| Accounts Payable, % | 54.51 | 19.99 | 15.42 | 8.58 | 7.43 | 21.19 | 21.19 | 21.19 | 21.19 | 21.19 |
| Capital Expenditure | -7.4 | -4.9 | -50.7 | -35.6 | -6.2 | -43.5 | -67.0 | -103.2 | -159.0 | -244.9 |
| Capital Expenditure, % | -69.24 | -15.69 | -90.79 | -36.93 | -9.68 | -44.47 | -44.47 | -44.47 | -44.47 | -44.47 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -96.0 | -125.8 | -211.0 | -279.2 | -190.5 | -95.0 | -146.4 | -225.4 | -347.2 | -534.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -95.3 | -132.7 | -256.7 | -331.2 | -145.3 | -119.1 | -184.9 | -284.8 | -438.6 | -675.6 |
| WACC, % | 8.94 | 8.92 | 8.9 | 8.77 | 8.95 | 8.9 | 8.9 | 8.9 | 8.9 | 8.9 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,239.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -689 | |||||||||
| Terminal Value | -9,991 | |||||||||
| Present Terminal Value | -6,524 | |||||||||
| Enterprise Value | -7,763 | |||||||||
| Net Debt | 62 | |||||||||
| Equity Value | -7,825 | |||||||||
| Diluted Shares Outstanding, MM | 98 | |||||||||
| Equity Value Per Share | -79.51 |
What You Will Get
- Pre-Filled Financial Model: Fate Therapeutics’ actual data allows for accurate DCF valuation.
- Full Forecast Control: Modify revenue growth, margins, WACC, and other essential metrics.
- Instant Calculations: Automatic updates provide immediate results as you adjust inputs.
- Investor-Ready Template: A polished Excel file crafted for high-quality valuation presentations.
- Customizable and Reusable: Designed for adaptability, enabling repeated use for comprehensive forecasts.
Key Features
- Customizable Research Variables: Adjust essential metrics such as clinical trial success rates, market penetration, and R&D expenditures.
- Instant DCF Valuation: Derives intrinsic value, NPV, and other financial outputs in real-time.
- High-Precision Analysis: Incorporates Fate Therapeutics’ actual financial data for accurate valuation results.
- Effortless Scenario Simulation: Evaluate various hypotheses and analyze results with ease.
- Efficiency-Boosting Solution: Avoid the complexity of constructing detailed valuation models from the ground up.
How It Works
- Download the Template: Gain immediate access to the Excel-based FATE DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and additional factors.
- Instant Calculations: The model automatically recalculates Fate Therapeutics’ intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential valuation shifts.
- Analyze and Decide: Leverage the results to inform your investment or financial analysis.
Why Choose This Calculator?
- User-Friendly Interface: Tailored for both newcomers and seasoned professionals.
- Customizable Inputs: Easily adjust parameters to suit your financial analysis.
- Real-Time Feedback: Observe immediate changes in Fate Therapeutics’ valuation as you modify inputs.
- Preloaded Data: Comes equipped with Fate Therapeutics’ actual financial metrics for swift evaluations.
- Endorsed by Experts: Utilized by investors and analysts for making well-informed decisions.
Who Should Use Fate Therapeutics, Inc. (FATE)?
- Investors: Make informed choices with a cutting-edge biotechnology investment analysis tool.
- Biotech Analysts: Streamline your research process with a comprehensive model tailored for biotech evaluations.
- Healthcare Consultants: Easily modify the framework for client pitches or industry reports.
- Biotechnology Enthusiasts: Enhance your knowledge of therapeutic innovations through practical case studies.
- Educators and Students: Utilize it as an effective resource in courses focused on biotechnology and finance.
What the Template Contains
- Historical Data: Includes Fate Therapeutics’ past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Fate Therapeutics’ intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Fate Therapeutics’ financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.